Cannabis-Based Medications for Generalized Anxiety Disorder and Post-Traumatic Stress Disorder

Current FDA-Approved Cannabinoid Indications

• The FDA has approved Epidiolex (CBD) exclusively for rare epilepsy syndromes and tuberous sclerosis complex, according to the American College of Physicians 1
• The FDA has approved Dronabinol (synthetic THC) only for chemotherapy-induced nausea/vomiting and AIDS-related anorexia, as stated by the American College of Physicians 1
• The FDA has approved Nabilone (synthetic cannabinoid) only as an antiemetic for chemotherapy-induced nausea/vomiting, as reported by the American College of Physicians 1

Critical Distinction: State Medical Marijuana Programs vs. FDA Approval

• Medical marijuana itself has not been FDA-approved for any indication, despite many states having legalized medical marijuana programs, according to the American Medical Association 2
• Cannabis remains federally classified as a Schedule I controlled substance with "no currently accepted medical use" and "high potential for misuse", as stated by the American College of Physicians 3

Evidence Status for PTSD and Anxiety

• Older adults using cannabis face higher risk for behavioral health issues including anxiety and depression, plus sedation, obtundation, and myocardial ischemia, as reported by the American Geriatrics Society 3
• Cannabis can paradoxically cause or exacerbate the same conditions it is intended to treat, including anxiety, according to the American Psychiatric Association 2

Clinical Pitfalls to Avoid

• Recognize that cannabis may worsen anxiety disorders rather than improve them, particularly in vulnerable populations, as warned by the American Academy of Child and Adolescent Psychiatry 3
• Adolescents face elevated risks including neurodevelopmental decline, psychotic disorders, depression, and suicidal ideation with cannabis use, as reported by the American Academy of Pediatrics 3
• Pregnant and breastfeeding individuals must avoid all cannabis products due to fetal brain development risks and increased premature birth risk, as advised by the American College of Obstetricians and Gynecologists 3

Current Research Gaps

• The American College of Physicians supports removing cannabis from Schedule I to facilitate rigorous research into potential therapeutic benefits, as stated by the American College of Physicians 4